Hwang to Sue U.S. Collaborator Over Stem Cell Patent
By Chosun Ilbo,
Chosun Ilbo
| 02. 14. 2006
Lawyers for the disgraced cloning scientist Hwang Woo-suk on Monday decided to take legal action against Hwang_s one-time collaborator Prof. Gerald Schatten, who is insisting on his right to a stem-cell technology patent. Schatten, of the University of Pittsburgh, is a co-author of Hwang_s discredited 2005 Science paper on patient-specific stem cells.
Hwang_s lawyers asked Seoul National University, to which Hwang transferred his right to apply for stem-cell related patents, to return the right to the scientist.
They said SNU was attempting to cancel the patent application since Hwang_s research results were fabricated, but Schatten, _who has done nothing to create stem cells,_ had no such compunction and was trying to make the patents for related technology his own. Their plan is to take legal action against Schatten once the university returns the rights.
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Ian Sample, The Guardian | 03.08.2024
Scientists are a step closer to making IVF eggs from patients’ skin cells after adapting the procedure that created Dolly the sheep, the first cloned mammal, more than two decades ago.
The work raises the prospect of older women being...
By Ramon Antonio Vargas, The Guardian | 02.28.2024
Doctors say a man in California who contracted blood cancer while living with HIV is in remission from both potentially fatal illnesses thanks to a treatment they are hailing as remarkable and encouraging.
Paul Edmonds is only the fifth-known person...
By Victoria Gray, Uduak Thomas, and Kevin Davies, The CRISPR Journal | 02.14.2024
In July 2019, medical staff in Nashville dosed the first U.S. patient in the exa-cel therapy trial, sponsored by Vertex Pharmaceuticals and CRISPR Therapeutics. That first patient was Victoria Gray, a mother of four from Forest, Mississippi, a sickle cell...